Brekken J - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Identification of new biomarkers for clinical trials of Hsp90 inhibitors.

Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. Zhang H, et al. Among authors: brekken j. Mol Cancer Ther. 2006 May;5(5):1256-64. doi: 10.1158/1535-7163.MCT-05-0537. Mol Cancer Ther. 2006. PMID: 16731758

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ. Lundgren K, et al. Among authors: brekken j. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758. Mol Cancer Ther. 2009. PMID: 19372565

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF. Kasibhatla SR, et al. Among authors: brekken j. J Med Chem. 2007 Jun 14;50(12):2767-78. doi: 10.1021/jm050752+. Epub 2007 May 8. J Med Chem. 2007. PMID: 17488003

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.

Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Shalinsky DR, et al. Among authors: brekken j. Ann N Y Acad Sci. 1999 Jun 30;878:236-70. doi: 10.1111/j.1749-6632.1999.tb07689.x. Ann N Y Acad Sci. 1999. PMID: 10415735

Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations.

Shalinsky DR, Brekken J, Zou H, Kolis S, Wood A, Webber S, Appelt K. Shalinsky DR, et al. Among authors: brekken j. Invest New Drugs. 1998-1999;16(4):303-13. doi: 10.1023/a:1006204901140. Invest New Drugs. 1998. PMID: 10426662

Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K. Shalinsky DR, et al. Among authors: brekken j. Clin Cancer Res. 1999 Jul;5(7):1905-17. Clin Cancer Res. 1999. PMID: 10430098

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6 results

Search Page

Filters